Malignancy screening in autoimmune myositis among Australian rheumatologists

Internal Medicine Journal

Volumn 47, Issue 12, 2017, Pages 1367-1375

  Dutton, Katherine ^a   Soden, Muriel ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

Author keywords

cancer; dermatomyositis; malignancy screening; polymyositis; rheumatology

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN ANTIBODY; TIF 1Y ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; AUSTRALIAN; AUTOIMMUNE DISEASE; AUTOIMMUNE MYOSITIS; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CLINICAL PRACTICE; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DELEGATION OF SCREENING; DEMOGRAPHY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ESOPHAGUS CANCER; HAZARD RATIO; HEMATOPOIETIC SYSTEM MALIGNANCY; HUMAN; KNOWLEDGE ON REPEATED SCREENING; LUNG CANCER; LYMPHATIC SYSTEM MALIGNANCY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASM; MAMMOGRAPHY; MEDICAL INFORMATION; MIDDLE AGED; MULTIPLE CHOICE TEST; MYOSITIS; NASOPHARYNX CANCER; ONLINE SYSTEM; ONSET AGE; OPEN RESPONSE QUESTION; OVARY CANCER; PANCREAS CANCER; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; REPEAT SCREENING; RHEUMATOLOGIST; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TEST SELECTION KNOWLEDGE; THORAX RADIOGRAPHY; TREND STUDY; UTERINE CERVIX CANCER; AUSTRALIA; DERMATOMYOSITIS; EARLY CANCER DIAGNOSIS; FEMALE; MALE; PROCEDURES; RHEUMATOLOGY; STANDARDS;

AUSTRALIA; AUTOIMMUNE DISEASES; DERMATOMYOSITIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MYOSITIS; RHEUMATOLOGISTS; RHEUMATOLOGY; SURVEYS AND QUESTIONNAIRES;

EID: 85037696389     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.13556     Document Type: Article

References (32)

1. Trallero-Araguas E, Rodrigo-Pendás JÁ, Selva-O'Callaghan A, Martínez-Gómez X, Bosch X, Labrador-Horrillo M et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis. Arthritis Rheum 2012; 64: 523–32.
2. Callen JP. Relation between dermatomyositis and polymyositis and cancer. Lancet 2001; 357: 85–6.
3. Olazagasti JM, Baez PJ, Wetter DA, Ernste FC. Cancer risk in dermatomyositis: a meta-analysis of cohort studies. Am J Clin Dermatol 2015; 16: 89–98.
4. Gallais V, Crickx B, Belaich S. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. Ann Dermatol Venereol 1996; 123: 722–6.
5. Tiniakou E, Mammen AL. Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol 2015; 52: 20–33.
6. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senécal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005; 84: 231–49.
7. Dalakas MC. Review: an update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 2011; 37: 226–42.
8. Aggarwal R, Oddis CV. Paraneoplastic myalgias and myositis. Rheum Dis Clin North Am 2011; 37: 607–21.
9. Lega JC, Fabien N, Reynaud Q, Durieu I, Durupt S, Dutertre M et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 2014; 13: 883–91.
10. Limaye V, Luke C, Tucker G, Hill C, Lester S, Blumbergs P et al. The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 2013; 33: 965–71.
11. Zampieri S, Valente M, Adami N, Biral D, Ghirardello A, Rampudda ME et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev 2010; 9: 449–53.
12. Acciavatti A, Avolio T, Rappuoli S, Foderi L, Soldati V, Franchi M et al. Paraneoplastic necrotizing myopathy associated with adenocarcinoma of the lung – a rare entity with atypical onset: a case report. J Med Case Rep 2013; 7: 112.
13. Beck EH, Amato AA, Greenberg SA. Inclusion body myositis and chronic lymphocytic leukemia: a case series. Neurology 2014; 83: 98–9.
14. Allenbach Y, Keraen J, Bouvier AM, Jooste V, Champtiaux N, Hervier B et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 2016; 139(Pt 8): 2131–5.
15. Qiang JK, Kim BW, Baibergenova A, Alhusayen R. Risk of malignancy in dermatomyositis and polymyositis: a systematic review and meta-analysis. J Cutan Med Surg 2017; 21: 131–6.
16. Yang Z, Lin F, Qin B, Liang Y, Zhong R. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 2015; 42: 282–91.
17. Wang J, Guo G, Chen G, Wu B, Lu L, Bao L. Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol 2013; 169: 838–47.
18. Basset-Seguin N, Roujeau JC, Gherardi R, Guillaume JC, Revuz J, Touraine R. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol 1990; 126: 633–7.
19. Nishikai M, Sato A. Low incidence of antinuclear antibodies in dermatomyositis with malignancy. Ann Rheum Dis 1990; 49: 422.
20. Duncan AG, Richardson JB, Klein JB, Targoff IN, Woodcock TN, Callen JP. Clinical, serologic, and immunogenetic studies in patients with dermatomyositis. Acta Derm Venereol 1991; 71: 312–6.
21. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 2013; 65: 2954–62.
22. Fiorentino D, Casciola-Rosen L. Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection. Arthritis Rheum 2012; 64: 346–9.
23. Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47: 324–8.
24. Lu X, Yang H, Shu X, Chen F, Zhang Y, Zhang S et al. Factors predicting malignancy in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. PLoS One 2014; 9: e94128.
25. Kang EH, Lee SJ, Ascherman DP, Lee YJ, Lee EY, Lee EB. Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. Rheumatology (Oxford) 2016; 55: 1631–41.
26. Selva-O'Callaghan A, Trallero-Araguás E, Grau-Junyent JM, Labrador-Horrillo M. Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol 2010; 22: 627–32.
27. Yoshinaga A, Hayashi T, Ishii N, Ohno R, Watanabe T, Yamada T. Successful cure of dermatomyositis after treatment of nonseminomatous testicular cancer. Int J Urol 2005; 12: 593–5.
28. Christie A, McKay N, Nussey F. Dermatomyositis as presenting feature of ovarian cancer, treated with neo-adjuvant chemotherapy and interval debulking surgery. Gynecol Oncol Case Rep 2013; 6: 13–5.
29. Callen JP. Dermatomyositis and multiple malignancies in a patient treated with methotrexate. J Surg Oncol 1983; 24: 113–6.
30. Tambe SA, Jerajani HR. Dermatomyositis associated with malignancy: a report of 3 cases. Indian Dermatol Online J 2013; 4: 326–32.
31. Selva-O'Callaghan A, Grau JM, Gámez-Cenzano C, Vidaller-Palacín A, Martínez-Gómez X, Trallero-Araguás E et al. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med 2010; 123: 558–62.
32. Australian Government Department of Health. MBS Online. Category 5 – diagnostic imaging services, 2017 [cited 2017 Aug 1]. Available from URL: http://www9.health.gov.au/mbs/search.cfm?q=PET&Submit=&sopt=S